Prescription Required
Veenat 400 Tablet is a targeted cancer therapy used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It contains Imatinib (400mg), a tyrosine kinase inhibitor (TKI) that blocks the action of proteins responsible for uncontrolled cell growth in cancer.
Seek guidance from your healthcare provider regarding the safety of consuming alcohol while taking this medication.
Veenat 400 Tablet is considered unsafe during pregnancy due to potential harm to the developing baby. Consult your doctor for personalized advice.
Exercise caution during breastfeeding with this medication, as limited data suggests potential harm to the baby.
Use Veenat 400 Tablet cautiously in individuals with kidney disease.
Exercise caution with this medication in severe liver disease.
Avoid driving if you experience dizziness, fatigue, or other side effects.
Imatinib Mesylate: Works by inhibiting the tyrosine kinase enzyme, which is responsible for the growth and proliferation of cancer cells. By blocking this enzyme, Imatinib Mesylate helps to prevent the growth and spread of cancer cells.
Chronic Myeloid Leukemia (CML) – A type of blood cancer where abnormal white blood cells multiply uncontrollably due to a genetic mutation. Gastrointestinal Stromal Tumors (GISTs) – A rare type of cancer that occurs in the digestive tract, affecting the stomach or intestines. Tyrosine Kinase Overactivity – The enzyme responsible for abnormal cancer cell growth, which Imatinib blocks.
Veenat 400 Tablet is a targeted cancer therapy drug that slows the progression of leukemia and GISTs by blocking abnormal protein signals. It is highly effective in improving survival rates and reducing cancer cell multiplication, but regular monitoring is required for side effects.
MBA in Pharmaceutical
Content Updated on
Friday, 28 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA